life scienc tool diagnost
top anim health pick boost estim target price remain
top pick anim health view double-digit earn growth
continu consist revenu growth improv cost structur
capit deploy opportun supplement growth follow latest
upsid encourag guidanc rais lift ep
reflect beat lower interest expens pt move
higher view risk includ shift fundament
demand slower traction new products/pipelin
innov itch recent receiv posit opinion combin
parasiticid simparica trio europ potenti eu approv
come month along on-going regulatori review multipl
geographi consist prior disclosur us commerci
simparica trio target ahead flea/tick season base
analysi parasiticid model simparica trio could gener
million sale ad bp y/i top-line growth net
estim exist parasiticid cannib million bp
suggest upsid current estim see note anim track
tripl revolut proheart simparica trio offer
comprehens portfolio best-in-class parasiticid span variou
formul topic inject chewabl sizeabl billion canin
parasiticid market bundl opportun thereon importantli
 project on-going emphas sever shot goal
note opportun felin pain mab critic unmet need
anim health note gener million atop dermat sale
impress continu momentum cytopoint us
ou apoquel us ou encourag dynam
innov portfolio matur
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
global leader develop anim health
therapeut livestock companion anim diversifi
portfolio product line directli market countri
industri largest sale forc
price aug rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky scenario assum meaning profit
contribut oper effici initi greater
expect adopt futur recent launch product
substanti share gain well stronger anticip growth
anim health fundament
grey sky scenario assum lower expect
ramp profit weaker traction new product potenti
distribut manufactur disrupt fx macroeconom
headwind weak companion product anim
review spoke manag ir follow
earn print updat guidanc disclosur key takeaway
reserv strong work capit manag oper effici initi
item absent morn earn report gener cash flow
oper million cash reserv stand billion
ttm net debt/ebitda within target rang ttm cash convers
cycl improv day predominantli lower inventori day remind
note expect maintain inventori level inventori day
earn recap ztss ep handili exceed estimate
consensu better revenu profit rais ep guidanc
midpoint vs consensu reflect
beat lower interest expens also ad
well estim us ahead plan
momentum companion anim vs estimate driven parasiticid apoquel
cytopoint abaxi us livestock also exceed estim
poultri swine promot activ partial off-set modest declin cattl
ex fx view notabl strength
companion vs estimate driven dermatolog simparica abaxi
out-performance also livestock vs estimate poultri favor comp
cattl partial off-set asf million gross margin improv meaning
bp bp plan meanwhil administr expens declin
bp bp plan contribut ebit margin expans bp bp
estim
oper guid hike rais oper top-line guidanc
includ oper revenu growth vs prior
report basi increas revenu guidanc million midpoint
million chang driven higher oper
growth increment favor fx forecast importantli target
organ oper sale growth ex-fx ex-abaxi vs prior
impli bp top-line contribut abaxi deal close juli
despit declin abaxi sale
dermatolog portfolio gener million sale impress
increas heel rise increas demonstr sustain
momentum apoquel million cytopoint million
us ou despit market share vs begin
see opportun expand market strength us faster
life-cycle innov apoquel speci also support
growth longer term remind launch apoquel china consist
intern timelin given pet medic rate current
rang china grow rapidli still far
penetr develop market traction may take longer build compar
develop market said new market entranc support growth
longer term veterinari practic protocol becom sophist china
view apoquel well posit region drive growth help ztss
figur quarterli apoquel sale yoy growth
million
figur proprietari cs survey us
veterinariansdo expect prescrib apoquel
greater patient year
credit suiss period except
posit parasiticid simparica revolut help drive organ
oper sale growth companion anim us
simparica gener million sale repres growth global
oper growth us support promot
invest lead increas penetr market share gain
simparica trio posit opinion eu recent receiv posit
opinion combin flea/tick/heartworm parasiticid committe
medicin product veterinari use cvmp europ juli product could
get full approv europ september/octob time-frame meanwhil
call manag also note regulatori review also underway
variou countri includ us canada australia brazil japan
potenti addit file china mexico later year broadli
anticip commerci simparica trio ahead flea/tick
season line prior forecast refer previou analysi
forecast sale million ad bp y/i top-line growth net
estim exist parasiticid cannib million bp
simparica trio tripl avail us market see note
proheart launch proheart prevent heartworm inject
month protect juli importantli proheart contribut
result given achiev fda approv quarter close product
begin contribut result
togeth revolut proheart simparica trio combin offer
veterinarian portfolio best-in-class parasiticid span variou formul
topic inject chewabl help meet need relev case
sizeabl billion canin parasiticid market see parasiticid market model
compani data credit suiss estim note revolut contribut revenu disclos disclos million
monoclon antibodi opportun abound highlight pain felin pain
critic unmet need anim announc file
us eu new monoclon antibodi candid control pain associ
osteoarthr felin expect receiv approv notabl
monoclon antibodi come nexvet portfolio illustr valu select
 innov importantli felin pain repres critic unmet need anim
health base survey work see note anim track chew vet
survey also process file similar osteoarthr product dog
albeit acknowledg canin version would like approv felin
product note current project on-going would over-
emphas one particular pipelin opportun sever shot goal
abaxi updat gener million revenu dognost
reflect y/i growth abaxi excl short
expect manag reiter abaxi add bp top-line growth
return dd growth support salesforc integr progress fulli
staf intern traction instrument placement consum
complet destock normal inventori level easier comp
dont expect legaci abaxi portfolio derail idexx laboratoriess
outperform growth trajectori nt view leverag global
commerci capabl expans oversea lt opportun livestock
attribut strength poultri includ antibiot altern
medic feed addit also benefit lack efficaci suppli constraint
competitor poultri product quarter experienc modest growth
swine portfolio larg driven promot activ quarter partial
off-set modest declin cattl cattl weak driven slower movement
cattl feedlot light wet weather
outsid us ztss livestock busi improv driven strong
perform poultri portfolio includ vaccin medic feed addit
cattl also contribut growth easi comp prior year neg
impact nation truck industri strike occur brazil meanwhil
swine flat y/i growth vaccin off-set impact african swine fever
china importantli china livestock declin oper asf latest
estim expect swine herd impact expect asf
impact full year revenu million million million
headwind bp intern livestock growth bp overal growth
continu highlight potenti offset increas product export china
brazil europ embed guidanc repres potenti
sourc upsid
salesforc expans ahead innov wave plan two
intern expans diagnost specialist end
expect complet second salesforc expans focus us companion
anim market decid undergo second salesforc expans light
sever new potenti companion anim product launch includ revolut
proheart juli simparica trio estimate monoclon antibodi
manag pain cat estimate like undisclos pipelin opportun
profit dynam ztss adjust gross margin eye-pop
highest histori public compani repres expans
bp y/i view higher gross margin like partial impact greater
mix companion anim sale revenu rel livestock
expect better cost sale percentag revenu
vs prior better experi previous expect
forecast step cost sale mix lap price increas benefit
experienc said better cost sale sale
partial off-set higher expect sg expens million
million higher expens million meanwhil line item
includ lower expect interest expens million lower effect tax rate
vs prior add vs prior estim rais adj
ep guidanc vs prior
robust cash flow flow oper million meaning higher
experi note accru expens declin approxim
million primarili reflect sever payment relat abaxi remind
previous note expect y/i declin oper cash flow result
flat inventori level well increas invest manufactur
capit deploy option net leverag ttm ebitda view
ampli dri power facilit deal state interest tangenti area
anim health includ genet greater foray data analyt
billion remain share repurchas author expect level share
repurchas continu million
annual revenu also quarter announc acquir platinum
perform family-own nutrition-focus anim health compani estimate
million deal ad estim million annual sale
expand exposur equin segment revenu ad
platinum inher higher margin flagship equin nutrit product also
offer tradit companion anim dog/cat also expand
platinum presenc platinum current sell directli veterinarian hors
owner e-commerc model could present new distribut
channel across speci segment deal expect close
year embed updat guidanc year rel
immateri
compani mention price
